TABLE 4.

The clinical trials of oncolytic virus from www.clinicaltrials.gov.

Oncolytic virus	Study type	Condition	Enrollment	Results
HF10	Innervational	Resectable Stage IIIB, IIIC, IVM1a melanoma	7	HF10 was used in combination with Nivolumab to treat melanoma patients in this clinical trial. The overall survival of patients was about 2 years and the pathologic complete response was 83.3% (a pathologic complete response was defined as no viable residual melanoma cells in the surgical specimen)
Oncolytic measles virus	Innervational	Ovarian cancer or primary peritoneal cavity cancer	37	27 of the 37 ovarian cancer or primary peritoneal cavity cancer patients achieved SD (stable disease) for 1 year
Coxsackievirus A21	Innervational	Stage IIIc and stage IV malignant melanoma	57	Percentage of participants with Immune-related progression-free survival (irPFS) at 6 months was 38.6% and the duration response rate was 21.1%
T-vec	Innervational	Stage IIIc and stage IV malignant melanoma	50	The objective tumor response rate of the participants was 28%. The duration of response was 223 days and the overall survival was 448 days